3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Neoplasm Metastasis
1
Carcinoma, Squamous Cell
1
Interventions
pembrolizumab
139
Cisplatin
76
Cetuximab
53
Carboplatin
49
Paclitaxel
39
Nivolumab
39
Radiotherapy
37
Docetaxel
34
Radiotherapy, Intensity-Modulated
30
Magnetic Resonance Spectroscopy
25
Specimen Handling
20
Fluorouracil
20
Platinum
14
1,2-diaminocyclohexaneplatinum II citrate
13
Taxes
12
cemiplimab
11
Radiation
11
Ipilimumab
11
atezolizumab
10
Surgical Procedures, Operative
10
Drug Therapy
10
tislelizumab
9
Biopsy
9
durvalumab
8
Radiosurgery
8
Albumin-Bound Paclitaxel
8
130-nm albumin-bound paclitaxel
8
Standard of Care
7
Chemoradiotherapy
7
Immune Checkpoint Inhibitors
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
ficlatuzumab
×
1 year
×
Clear all
NCT06064877
2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3
Recruiting
410 enrolled